Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib alone and with EPOCH in relapsed/refractory DLBCL
NCT00054665Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2003
- Primary completion
- Sep 2008
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by National Cancer Institute. Started Feb 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00054665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054665.